Apellis Pharmaceuticals (NASDAQ:APLS) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $57.00 price objective on the stock.

A number of other brokerages have also commented on APLS. Citigroup dropped their price objective on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Needham & Company LLC cut their price target on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Wells Fargo & Company reduced their price objective on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Robert W. Baird dropped their target price on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Finally, The Goldman Sachs Group cut Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 target price on the stock. in a research note on Tuesday, December 17th. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $45.71.

Apellis Pharmaceuticals Stock Down 4.3 %

NASDAQ:APLS opened at $24.06 on Monday. Apellis Pharmaceuticals has a 1 year low of $23.81 and a 1 year high of $66.00. The stock has a 50-day moving average price of $29.88 and a two-hundred day moving average price of $31.48. The stock has a market cap of $2.99 billion, a price-to-earnings ratio of -11.85 and a beta of 0.96. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.08. The business had revenue of $212.50 million during the quarter, compared to analyst estimates of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. Apellis Pharmaceuticals’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.73) EPS. As a group, equities analysts expect that Apellis Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Transactions at Apellis Pharmaceuticals

In related news, insider Caroline Baumal sold 2,816 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $33.81, for a total transaction of $95,208.96. Following the completion of the transaction, the insider now owns 55,560 shares in the company, valued at approximately $1,878,483.60. This trade represents a 4.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO James George Chopas sold 1,096 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total value of $33,351.28. Following the completion of the sale, the chief accounting officer now owns 48,138 shares in the company, valued at $1,464,839.34. This represents a 2.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 60,365 shares of company stock worth $1,810,479 in the last ninety days. Insiders own 6.80% of the company’s stock.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Toronto Dominion Bank raised its position in shares of Apellis Pharmaceuticals by 3,791.4% in the fourth quarter. Toronto Dominion Bank now owns 997,053 shares of the company’s stock valued at $31,816,000 after purchasing an additional 971,431 shares during the period. GF Fund Management CO. LTD. acquired a new position in Apellis Pharmaceuticals in the 4th quarter valued at about $83,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Apellis Pharmaceuticals by 11.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 212,887 shares of the company’s stock valued at $6,793,000 after acquiring an additional 21,822 shares during the period. Woodline Partners LP lifted its position in Apellis Pharmaceuticals by 0.5% during the fourth quarter. Woodline Partners LP now owns 189,477 shares of the company’s stock worth $6,046,000 after acquiring an additional 913 shares during the last quarter. Finally, Vident Advisory LLC bought a new stake in shares of Apellis Pharmaceuticals during the fourth quarter worth approximately $465,000. 96.29% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).